Scholarlink

Purpose <p>This study investigates whether different morphological features affect the best-corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with diabetic macular edema (DME) undergoing anti–vascular endothelial growth factor (anti-VEGF) therapy.</p> Methods <p>We retrospectively collected data from 727 eyes of 464 patients with DME who received either ranibizumab or aflibercept. We constructed mixed-effects regression models to determine if different morphological features shown on optical coherence tomography would affect post-treatment BCVA and CMT after controlling for clinical variables. In eyes with ellipsoid zone disruption (EZD), the relationship between baseline BCVA and achieving a final CMT &lt; 200&#xa0;μm was further examined.</p> Results <p>After 24 months of anti-VEGF treatment, patients demonstrated improvements in BCVA and reductions in CMT. Poorer post-treatment BCVA was associated with older age, longer treatment duration, EZD (<i>p</i> = 0.017) and disorganization of the retinal inner layers (DRIL) (<i>p</i> = 0.001). Excessive macular thinning (final CMT &lt; 200&#xa0;μm) was more frequently observed in eyes with EZD, particularly among those with a baseline BCVA &lt; 15 ETDRS letters, in exploratory subgroup analyses. The association appeared more pronounced among individuals with increased hyperreflective foci (HRF) in the outer retina.</p> Conclusion <p>In DME eyes with EZD, a poorer baseline BCVA and increased HRF appear to be statistically associated with excessive macular thinning following anti-VEGF treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of excessive macular thinning in diabetic macular edema with ellipsoid zone disruption treated with anti-VEGF: 2-year real-world evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Yu-Kuei Lee,
  • Sheng-Min Hsu,
  • Chun-Hsiang Chang,
  • Jia-Horung Hung,
  • Yi-Sheng Chang,
  • Chia-Hua Lee,
  • Jung-Der Wang

摘要

Purpose

This study investigates whether different morphological features affect the best-corrected visual acuity (BCVA) and central macular thickness (CMT) in patients with diabetic macular edema (DME) undergoing anti–vascular endothelial growth factor (anti-VEGF) therapy.

Methods

We retrospectively collected data from 727 eyes of 464 patients with DME who received either ranibizumab or aflibercept. We constructed mixed-effects regression models to determine if different morphological features shown on optical coherence tomography would affect post-treatment BCVA and CMT after controlling for clinical variables. In eyes with ellipsoid zone disruption (EZD), the relationship between baseline BCVA and achieving a final CMT < 200 μm was further examined.

Results

After 24 months of anti-VEGF treatment, patients demonstrated improvements in BCVA and reductions in CMT. Poorer post-treatment BCVA was associated with older age, longer treatment duration, EZD (p = 0.017) and disorganization of the retinal inner layers (DRIL) (p = 0.001). Excessive macular thinning (final CMT < 200 μm) was more frequently observed in eyes with EZD, particularly among those with a baseline BCVA < 15 ETDRS letters, in exploratory subgroup analyses. The association appeared more pronounced among individuals with increased hyperreflective foci (HRF) in the outer retina.

Conclusion

In DME eyes with EZD, a poorer baseline BCVA and increased HRF appear to be statistically associated with excessive macular thinning following anti-VEGF treatment.